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Early reperfusion remains the most effective way of limiting 
myocardial necrosis and improving ventricular function in 
experimental models and human patients. However, the 
introduction of oxygen and cellular elements, especially the 
neutrophil, into the ischemic zone may initiate a deleterious 
cascade of events that limits myocardial salvage after 
reperfusion. Although the pathogenesis of reperfusion in- 
jury remains controversial, recent studies have suggested 
that the endothelium may play a critical role. 
Endothelial cells maintain flow in the microcirculation 
by secreting a number of vasodilatory compounds and 
substances that prevent plugging of capillaries by inhibiting 
Early reperfusion remains the most effective way of reducing 
infarct size and improving ventricular function in animal 
models and human patients (l-6). However, in the late 
1970s it was suggested (7) that reperfusion itself may have 
deleterious effects on the ischemic myocardium. Biochemi- 
cal and structural changes resulting from reperfusion may 
generate arrhythmias, result in prolonged left ventricular 
dysfunction (“myocardial stunning”) and limit the amount 
of potentially salvageable myocardium by the conversion of 
reversibly injured myocytes to irreversibly injured cells (S- 
IO). The death of previously viable myocytes attributable to 
reperfusion has been termed “reperfusion injury.” Although 
the concept of reperfusion injury is not universally accepted, 
studies (11-13) that temporally link an intervention in the 
perireperfusion period to myocardial salvage lend strong 
support to such a phenomenon. 
Reperfusion injury has been demonstrated (11-13) in 
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neutrophil adherence and platelet aggregation. Reperfusion 
of ischemic myocardium accelerates structural and func- 
tional changes in endothelial cells, resulting in a progressive 
decrease in microcirculatory Row (“no reflow” phenome- 
non). Numerous studies suggest that activated neutrophils 
mediate vascular damage by releasing reactive oxygen 
species and potent proteolytic enzymes. The administration 
of therapeutic agents that limit endothelial disruption and 
neutrophil plugging has shown promising results in limiting 
myocardial reperfusion injury in experimental models. 
(J Am Co11 Cardiol1989;13:450-9) 
animal models by the use of different therapeutic agents that 
significantly reduce infarct size. Studies aimed at determin- 
ing the significance of reperfusion injury in patients are in 
progress. However, the failure in some studies (4,14) to 
prevent myocardial necrosis, as evidenced by electrocardio- 
graphic (ECG) Q waves or persistent defects on thallium 
tomographic images, by the early administration of throm- 
bolytic agents (cl.5 and ~3.5 h) suggests that reperfusion 
injury may be clinically important. 
The pathogenesis of reperfusion injury is under intense 
investigation. Recent studies (13,15) have shown that the 
endothelium may play a central role in the evolution of 
reperfusion injury. This review highlights the important 
physiologic functions of the myocardial capillary endothe- 
lium, endothelial changes that occur with ischemia and 
reperfusion and the potential contribution of these changes 
to reperfusion injury. The role of various therapeutic agents 
will also be discussed. 
Function of the Myocardial Endothelium 
Recent experimental evidence (16,17) has demonstrated 
that the endothelial cell is active under both physiologic and 
pathophysiologic conditions. Endothelial cells account for 
an exceptionally high surface area in the heart (1,000 cm*/g) 
and form a continuous lining of the vasculature. This lining 
provides a selective barrier separating intra- and extravascu- 
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lar spaces, and the endothelial cell is, therefore, in a position 
to regulate the transfer of nutrients to myocytes, the diape- 
desis of leukocytes and the interaction between circulating 
vasoactive substances and vascular smooth muscle (18). 
The luminal plasmalemma of the endothelial cell supports 
a negatively charged glycocalyx, which tends to repel neu- 
trophils and thus limit adherence (19). In addition, this 
glycocalyx is antithrombogenic because it contains heparin, 
antithrombin III and thrombomodulin, an activator of pro- 
tein kinase C (17). Finally, endothelial cells have surface 
receptors for many vasoactive compounds, including acetyl- 
choline, histamine, serotonin, catecholamines, bradykinin 
and adenine nucleotides, reflecting the integral involvement 
of the endothelium in regulating vascular smooth muscle 
tone (17). 
Endothelium-derived relaxation factor. Myocardial endo- 
thelial cells are metabolically very active and are known to 
synthesize and secrete a variety of compounds that act to 
maintain microcirculatory flow (20). These include plasmin- 
ogen activator and antithrombin III, which inhibit coagula- 
tion, prostacyclin (PGI,), which limits platelet aggregation 
and neutrophil adherence and relaxes vascular smooth mus- 
cle and endothelial-derived relaxation factor (17,18,21-24). 
The functionally intact endothelium releases endothelial- 
derived relaxation factor in response to endogenous circu- 
lating compounds such as acetylcholine and serotonin 
(21.22). It has been shown (25,26) that endothelial-derived 
relaxation factor is indistinguishable from nitrous oxide, has 
a short life (6 to 50 s) and produces smooth muscle relaxation 
by increasing cyclic guanosine 3’5’ monophosphate (GMP!. 
Besides being a potent coronary vasodilator, endothelial- 
derived relaxation factor may also scavenge reactive oxygen 
species and inhibit platelet aggregation (27). 
Neutrophil adherence to eqdothelial cells. Recent evi- 
dence (19) highlights the importance of the endothelium in 
modulation of local inflammatory and immune responses. 
Adherence of neutrophils to the endothelial cell is of prime 
importance because it is the initiating step in inflammation. 
The endothelium produces substances that promote and 
inhibit neutrophil adherence. Endothelial membrane damage 
by trypsin increases neutrophil adherence, suggesting the 
presence of specific surface membrane proteins for neutro- 
phi] attachment (28). These tissue adherence molecules may 
be induced by circulating compounds such as chemotactic 
factors (29). The monokines, interleukin 1 and tumor necro- 
sis factor, have been shown (30) to induce the expression of 
an antigen on endothelial cell surfaces, which increases 
leukocyte adhesiveness. In addition, the endothelium syn- 
thesizes platelet-activating factor, a potent neutrophil stim- 
ulating agent. and secretes neutrophil chemoattractants 
(19.31). Endothelial cells are also known to produce several 
factors that inhibit neutrophil attachment, including adeno- 
sine, prostacyclin, and cyclic adenosine monophosphate 
(AMP) (17,18,32). The balance between induction and sup- 
pression of neutrophil adherence is related to the physiologic 
or pathologic environment, and further work is required to 
unravel the regulatory signals of these cellular interactions. 
Myocardial metabolism of adenosine. Finally, the endo- 
thelium plays a pivotal role in the myocardial metabolism of 
adenine nucleotides (33). Adenine tri-, di- and monophos- 
phates are present in a 3-fold greater concentration and 
adenosine in a 40-fold greater concentration in cultured 
endothelial cells compared with that in myocardial cells (18). 
Vascular endothelial cells, by means of their high capacity to 
release and take up adenosine, are responsible for the 
maintenance of constant plasma levels of this nucleoside in 
the coronary circulation (34,35). Adenosine is a potent 
coronary arteriolar vasodilator and may be an important 
regulator of coronary blood flow (34). In addition, adenosine 
deaggregates platelets and inhibits their release of thrombox- 
ane, a vasoconstrictor (36). Recent studies indicate that 
adenosine may also modulate neutrophil function. Both 
adenosine and adenosine analogues markedly reduce super- 
oxide anion generation by stimulated neutrophils. and aden- 
osine inhibits the adherence of activated neutrophils to 
cultured endothelial cells (32.37). 
Biochemical and Structural Changes in the 
Endothelium With Ischemia and Reperfusion 
Biochemical changes during ischemia (Fig. 1). Several bio- 
chemical changes occur within the endothelium during ische- 
mia and may predispose the microvasculature to extensive 
injury at the time of reperfusion. Severe hypoxia results in a 
rapid conversion from aerobic to anaerobic metabolism in 
the cell. High energy phosphates such as adenosine tri- and 
diphosphates are depleted within minutes, and protons. 
lactate and inorganic phosphates accumulate (38,39). Intra- 
cellular acidosis inactivates the sodium-potassium-adeno- 
sine triphosphatase pump. with a loss of normal transmem- 
brane ionic homeostasis. The resultant calcium influx has 
been shown (40) to activate endogenous phospholipases, 
possibly disrupting membrane integrity. Changes in the 
membrane may be responsible for deposition of complement 
on the plasmalemma of ischemic endothelial cells. It has 
been shown (4 I) that the complement fragment Clq acts as a 
chemoattractant, facilitating neutrophil adhesion to the 
ischemic endothelium. Membrane disruption may also be 
responsible for the loss of numerous protective free radical- 
scavenging enzymes such as superoxide dismutase, glutathi- 
one peroxidase and catalase (42). The ischemic endothelial 
cell is, therefore, vulnerable to oxidant injury, especially 
during reperfusion, when a burst of free radical production 
occurs (43). Impairment of membrane integrity may also 
result in the loss of adenine nucleotides, endothelial-derived 
relaxation factor and prostacyclin, thereby impairing the 
cell’s ability to regulate vasomotor tone in the microvascu- 
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Figure 1. Schematic diagram illustrating the potential role of the 
endothelial cell in myocardial reperfusion injury. ADO = adenosine; 
CAMP = cyclic adenine monophosphate; CAT = catalase; EDRF = 
endothelial-derived relaxing factor; GP = glutathione peroxidase; 
PGI, = prostacyclin; PLAT = platelet; PMN = polymorphonuclear 
leukocyte; SO; = superoxide anion; 4 SOD = reduction in super- 
oxide dismutase; TXA, = thromboxane AZ; XD = xanthine dehy- 
drogenase; X0 = xanthine oxidase. 
lature. This loss of vasodilatory reserve is thought to be 
augmented at reperfusion as a result of increased washout. 
The calcium influx during ischemia has also been shown 
(44) to activate a cytosolic protease that converts xanthine 
dehydrogenase to xanthine oxidase. Xanthine dehydroge- 
nase is an enzyme that catabolizes purine nucleotides and is 
localized primarily within the endothelium in myocardial 
tissue (45). The conversion of this enzyme to its oxidase 
form results in the production of the superoxide free radical 
when the necessary substrates are available, (namely, hypo- 
xanthine, which accumulates during ischemia and oxygen 
introduced at reperfusion) (44). In addition to deleterious 
intracellular effects, the superoxide anion is also thought to 
act as a neutrophil chemoattractant, probably through inter- 
action with a lipid noncovalently bound to serum albumin 
(46). A 1,500 dalton lipid serving as a neutrophil attractant 
has recently been isolated from cultured human endothelial 
cells (47). 
thought that damage to endothelial cells at reperfusion is 
mediated by free radicals or neutrophil-endothelial interac- 
tions, or both (Fig. 1) (19,53-56). Oxygen free radicals are 
highly reactive compounds containing an oxygen atom with 
an unpaired electron. These substances are cytotoxic, result- 
ing in lipid peroxidation of cellular membranes and denatur- 
ation of proteins and nucleic acids (Fig. 3) (55,56). The 
introduction of oxygen at reperfusion provides the final 
substrate for the activity of xanthine oxidase on the hypo- 
xanthine pool present in the ischemic endothelial cell (44). It 
has been hypothesized that this pathway results in the 
production of large quantities of the superoxide free radical 
at a time when the cell is vulnerable because of depletion of 
its antioxidant enzymes (42,46). However, studies (57-59) 
utilizing the competitive xanthine oxidase inhibitor allopuri- 
nol have shown conflicting results on infarct size reduction 
in the canine reperfusion model. It was suggested (58,60,61) 
that this discrepancy resulted from insufficient conversion of 
ailopurinol to its active metabolite oxypurinol, a more po- 
tent, noncompetitive inhibitor of xanthine oxidase. How- 
ever, oxypurinol also failed to reduce infarct size in a canine 
reperfusion model when studied in our laboratory (62), a 
finding that suggests that the xanthine oxidase pathway is 
not the primary source of free radicals in reperfused tissue. 
In addition, the role of xanthine oxidase as a source of free 
radicals in humans remains unclear. Xanthine oxidase ap- 
pears to be either absent or present in small quantities in the 
human heart (63.64). Because the enzyme has been found to 
be highly compartmentalized in some species, further stud- 
ies are needed to clarify its role in human patients (65). 
Structural changes during ischemia and reperfusion (Fig. Oxygen free radicals and reperfusion injury. Additional 
2). A marked disparity is noted histologically in the micro- sources of free radicals include reduced nicotinamide ade- 
circulation between models of permanent occlusion and nine dinucleotide phosphate oxidase in the neutrophil and 
reperfusion (48-50). Structural capillary changes in the per- alternative metabolic pathways in the endothelium (55.66). 
manent occlusion model are only readily apparent after Cyclooxygenase and lipooxygenase pathways, the mito- 
prolonged ischemic times (>90 min) and consist of free- 
floating intraluminal membrane-bound bodies with swelling 
of the endothelium and loss of pinocytotic vesicles (Fig. 2) 
(48,49). In contrast, reperfusion at 45 to 90 min of ischemia 
results in extensive disruption of the microvasculature (50). 
Histologic changes include capillary obstruction by endothe- 
lial cell swelling, loss of pinocytotic vesicles, protrusions, 
breaks in endothelial cells, disruption of the basement mem- 
brane and nuclear chromatin clumping. Although leukocytes 
begin to accumulate and adhere to ischemic endothelium, 
neutrophil adherence is significantly increased at the time of 
reperfusion (5 1,52). These neutrophils obstruct capillary 
lumens usually in association with fibrin and red cell plugs 
(15,50). 
Mechanisms of Endothelial Damage 
at Reperfusion 
Oxygen free radicals and xanthine oxidase therapy. It is 
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Figure 2. Electron micrographs of (A) border zones from a perma- 
nent 3 day coronary occlusion model, (B and C) blood reperfusion 
infarct after 90 min of occlusion. (D and E) intracoronary infusion of 
perfluorochemical after 90 min of reperfusion and (F) intracoronary 
infusion of adenosine after 90 min of coronary occlusion. A, 
Endothelial cell swelling (arrow) with intraluminal membrane-bound 
bodies (arrowheads) in the border zone of a permanent coronary 
occlusion infarct at 3 days. B, Marked endothelial swelling with 
cellular protrusions (arrowheads) that are totally obstructing 
the capillary lumen. C, Polymorphonuclear leukocyte sticking to 
endothelial cell within capillary lumen, which is a prominent feature 
of reperfused infarcts. D and E, Animal treated with pertluoroche- 
mical, showing only mild endothelial swelling and occasional mem- 
brane-bound structures (D, arrowheads) with prominent pinocytotic 
vesicles (E, arrowheads). F, Capillary from an animal treated with 
adenosine. Note mild endothelial swelling and the increase in 
endothelial cell folds (A, x8.600; B, x 10,400; C, x6,600; D, x4.400: 
E, ~4,500: F, x330: reduced by 277~~). 
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Figure 3. Schematic diagram illustrating some of 
the pathways involved in free radical production 
and sites of potential therapeutic intervention. 
The hydroxyl radical @OH) can be formed in the 
presence of catalytic iron via Haber-Weiss or 
Fenton reactions. ALLOP = allopurinol; ATP = 
adenosine triphosphate; DNA = deoxyribonu- 
cleic acid; GSH = reduced glutathione; GSSG = 
oxidized glutathione; MPG = N-2-mercaptopro- 
pionyl glycine; NAC = N-acetylcysteine; NADP 
= oxidized nicotinamide adenine dinucleotide 
phosphate; NADPH = reduced nicotinamide ad- 
enine dinucleotide phosphate; OH’ = hydroxyl 
radical; OXI = oxypurinol; SOD = superoxide 
dismutase, SO; = superoxide anion; X.0. = 
xanthine oxidase. 
chondrial electron transport chain, aldehyde oxidase and 
flavoproteins may also be involved in intracellular free 
radical production (55). The importance of nonneutrophil, 
intracellular free radical production is suggested by the 
enhanced myocardial salvage observed in neutropenic dogs 
treated with mercaptopropionyl glycine, a free radical scav- 
enger known to cross cellular membranes (67,68). The 
beneficial effects of the free radical-scavenging enzymes 
superoxide dismutase and catalase in reperfusion models 
amenable to salvage (occlusion time between 1 and 3 h) 
further support the role of free radicals in reperfusion injury 
(12,69,70). The large molecular weights of these compounds 
and their inability to cross cell membranes suggest that they 
are active against extracellular free radicals (71). By reduc- 
ing the intravascular concentration of the superoxide anion, 
these agents may interfere with neutrophil chemotaxis and 
adherence to endothelial cells (46). 
Oxygen free radicals, reperfusion arrhythmias and myo- 
cardial stunning. In addition to myocyte death, free radicals 
have been implicated in the pathogenesis of reperfusion- 
induced arrhythmias and the prolonged left ventricular dys- 
function (“myocardial stunning”) after reperfusion (8,9). 
Although the mechanisms remain unknown, it is postulated 
that free radicals disrupt cellular membranes by means of 
lipid peroxidation and thereby enhance abnormal ionic shifts 
both intercellularly, promoting reentrant circuits, and intra- 
cellularly, disrupting sarcoplasmic reticular regulation. 
Endothelial-Neutrophil Interactions 
Neutrophil adherence. The first step in neutrophil accu- 
mulation in the heart involves interaction between neutro- 
phils and the endothelium (neutrophil adherence) (19). Al- 
though a continuous physiologic interaction normally occurs 
between the neutrophil and the endothelium, hypoxic endo- 
thelial injury augments neutrophil adherence in vitro (19). It 
has recently been shown (5152) that the process of neutro- 
phi1 accumulation in the heart, which commences during 
ischemia, is markedly accelerated by reperfusion. It is 
controversial whether neutrophil adherence results primarily 
from changes in the endothelium, the neutrophil or probably 
both (19). 
Several types of endothelial injury may increase neutro- 
phi1 adherence (72-75). Damaged endothelial cells express 
membrane receptors for immunoglobulin and complement 
fragments that promote neutrophil adherence, and it has 
been shown (41,74) that the complement fragment Clq local- 
izes to ischemic myocardium in vivo. 
Substances that inhibit neutrophil adherence. Numerous 
substances in the functionally intact endothelium inhibit 
neutrophil adherence. Adenosine is known to reduce adher- 
ence of stimulated human neutrophils to cultured endothelial 
cells, and prostacyclin and cyclic adenosine monophosphate 
(AMP) have also been implicated as potential endothelial- 
derived inhibitors (19,23,32). Depletion of endothelial stores 
of adenosine, cyclic AMP and prostacyclin during ischemia 
may be exacerbated by washout at reperfusion, and the 
inability of the endothelium to secrete these compounds may 
contribute to the increased neutrophil accumulation with 
reperfusion. 
Substances that promote neutrophil adherence. Neutro- 
phils activated by chemotactic factors such as complement, 
superoxide anion, leukotrienes and platelet-activating factor 
undergo changes in membrane charge, degranulation and 
release of specific enzymes promoting adhesion (19). Acti- 
vated neutrophils adherent to the vessel wall also release 
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toxic products that may damage endothelial cells and alter 
their function (76). Neutrophil granules contain a number of 
compounds capable of producing vascular injury, including 
hypochlorous acid formed by myeloperoxidase and proteo- 
lytic enzymes (77). Lysosomal enzymes such as elastase 
have been shown to digest vascular basement membranes in 
vivo and in vitro (53). In addition, reactive oxygen metabo- 
lites (free radicals) produced by the neutrophil disrupt endo- 
thelial membranes by means of lipid peroxidation (54). 
Neutrophil-derived oxidants also inactivate antiproteases 
present in serum (78). Neutrophil degranulation and free 
radical release may, therefore, permit an unchecked activity 
of proteolytic enzymes on endothelial cell membranes. 
Endothelial Damage and the 
“No Reflow” Phenomenon 
In 1974, Kloner et al. (50) observed that the reperfusion of 
myocardium subjected to 90 min of ischemia was associated 
with an incomplete return of blood flow to some areas of the 
microcirculation. They termed this phenomenon “no 
reflow.” Numerous mechanisms were postulated, including 
perivascular swelling, interstitial hemorrhage, endothelial 
cell damage and capillary plugging by blood elements 
(lOSO). This concept of no reflow was extended a decade 
later with the observation that there is a continual decrease 
in blood flow to areas of ischemia after the onset of reper- 
fusion (79). This observation suggests a dynamic process of 
microcirculatory failure and probably represents an impor- 
tant mechanism in reperfusion injury (Fig. 1). 
Causes of no reflow phenomenon. Although the cause of 
progressive no reflow after reperfusion has not been pre- 
cisely defined, the endothelium is thought to play a key role 
because reperfusion is associated with a degree of endothe- 
lial disruption not present in preparations of permanent 
occlusion after comparable durations of ischemia (48-50). 
Mechanical (capillary obstruction by endothelial cell protru- 
sions and aggregated blood elements) or functional endothe- 
lial derangements, or both, may be involved (15,49-51). 
Intact endothelial cells regulate coronary vascular reactivity 
by the release of endothelial-derived relaxation factor, aden- 
osine and prostacyclin (18,21,22). In vitro relaxation of 
coronary artery segments to thrombin is attenuated in dogs 
that underwent ischemia and reperfusion in vivo (80). In 
addition, it was recently shown (81) that hypoxic and anoxic 
endothelial cells are capable of releasing a vasoconstrictol 
substance. This compound, recently isolated from porcine 
aortic endothelium, is a 21 residue peptide with a long 
half-life (40 to 60 min) (82). The inability of damaged 
endothelial cells to release relaxing factors into a vasocon- 
stricted bed may contribute to the progressive decline in 
blood flow that occurs after successful reperfusion. 
Endothelial-neutrophil interactions during reperfusion. 
Changes in the endothelial cell membrane during ischemia 
may enhance neutrophil-endothelial interactions at reperfu- 
sion. Engler et al. (51,52) demonstrated that neutrophil 
accumulation begins during ischemia and that this accumu- 
lation is significantly enhanced by blood reperfusion. His- 
tologic analysis demonstrated neutrophil plugging of up to 
27% of the capillaries in ischemic tissue in animals reper- 
fused with whole blood, whereas capillary plugging and the 
no reflow phenomenon were virtually abolished when dogs 
were reperfused with leukocyte-depleted blood (51). In 
addition to direct mechanical plugging of capillaries, neutro- 
phils interacting with a damaged endothelium may perpetu- 
ate no reflow by other mechanisms. Activated neutrophils 
release vasoactive substances such as leukotrienes and 
platelet-activating factor that promote vasoconstriction and 
enhance vascular permeability (76,83). Adhering neutrophils 
also secrete proteolytic enzymes and free radicals that 
further disrupt the endothelium and may contribute to pro- 
gressive capillary obstruction by endothelial membrane pro- 
trusions. 
Continued neutrophil-endothelial interactions result in 
the loss of the structural integrity qf‘ the endothelium. 
Breakdown of this barrier exposes vascular smooth muscle 
cells to potential circulating vasoconstrictors such as sero- 
tonin from platelets (21,22). Aggregated platelets, which 
have been seen by electron microscopy in plugged capillar- 
ies, may also exacerbate no reflow by releasing thromboxane 
and platelet-activating factors, thereby further enhancing 
vasoconstriction and neutrophil adherence, respectively 
(15,84). 
Therapeutic Interventions That May Limit 
Microvascular Disruption 
Microvascular disruption appears to result from the inter- 
action between activated neutrophils and an endothelium 
damaged by ischemia. The flow diagram in Figure 1 illus- 
trates the role of various substances that either enhance or 
protect against microvascular injury. The processes are 
complex, involving interactions between circulating neutro- 
phils, platelets and a disrupted or dysfunctional endothelial 
cell, or both. Our current understanding of the pathogenesis 
of this interaction suggests several potential therapeutic 
interventions. These include agents that interfere with the 
inflammatory response, such as endothelial cell receptor 
antagonists, antineutrophil agents and free radical scaven- 
gers. 
Perfluorochemicals. These are substances with a small 
particle size, low viscosity and high oxygen-carrying capac- 
ity (1 I). We have shown (85) that intracoronary administra- 
tion of the perlluorochemical (Fluosol-DA 20%) after reper- 
fusion in dogs subjected to 90 min of ischemia results in a 50 
to 60% reduction in infarct size and improved regional 
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ventricular function over a 2 week postreperfusion period. 
An additional study (1.5) using the canine reperfusion model 
demonstrated preservation of endothelial cell structure and 
function in animals treated with pertluorochemical. Light 
microscopy revealed the presence of neutrophils predomi- 
nantly within vessels in the ischemic zones in control ani- 
mals only. Electron microscopy showed capillary obstruc- 
tion by endothelial cell protrusions and neutrophil and red 
cell plugging in control animals, but a relatively intact 
endothelium and predominantly unobstructed capillaries in 
treated animals (Fig. 2). 
Perfluorochemicals and antineutrophil actions. This labo- 
ratory and others (86,87) have previously demonstrated that 
the perfluorochemical mixture reduces neutrophil chemo- 
taxis, adherence and superoxide production in vitro. These 
antineutrophil effects were also demonstrated (88) in granu- 
locytes removed from dogs treated with intravenous perfluo- 
rochemical. The intravenous administration of perfluoro- 
chemical during the last 30 min of a 90 min occlusion reduced 
leukocyte demargination during the critical period of myo- 
cardial reperfusion and significantly inhibited neutrophil 
chemotaxis into the ischemic myocardium (88). The suppres- 
sion of neutrophil infiltration reduced leukocyte plugging and 
endothelial disruption while significantly limiting infarct size 
in the treated group (88). Further work (89) demonstrated 
that preincubation of stimulated neutrophils with perfluoro- 
chemical resulted in significantly decreased adherence and 
cytotoxicity to cultured endothelial cells subjected to anoxia 
and re-oxia. In contrast, when endothehal cells were pre- 
incubated with perlluorochemical, no decrease in neutrophil 
adherence was observed (89). These studies suggest that 
perfluorochemicals may preserve the endothelium and, thus, 
limit reperfusion injury by means of their antineutrophil 
actions. 
Anti-free radical agents: N-acetylcysteine. The efficacy of 
anti-free radical agents in limiting reperfusion injury remains 
controversial (90). The two most widely studied agents are 
the free radical scavengers superoxide dismutase and cata- 
lase (Fig. 3). As noted previously (12,69,70), these agents 
have shown promising results in reperfusion animal models 
subjected to ischemic times of 1 to 3 h. However, the 
combination of these free radical scavengers failed to reduce 
infarct size when studied in canine reperfusion models with 
40 min and 3 h occlusions (91,92). In view of these contro- 
versial results, we explored the role of N-acetylcysteine, a 
low molecular weight precursor of glutathione, on myocar- 
dial reperfusion injury (93). N-acetylcysteine was chosen 
because it has been postulated to act on multiple sites in the 
production and propagation of free radicals. These include 
replenishment of glutathione stores, increasing cytoplasmic 
superoxide dismutase activity, scavenging the hydroxyl free 
radical and interfering with autocatalytic lipid peroxidation 
(Fig. 3) (93). N-acetylcysteine given 30 min into a 90 min 
occlusion failed to reduce infarct size when examined 24 h 
after reperfusion (94). Because free radicals are extremely 
short-lived and theoretically act locally, studies with anti- 
free radical agents are plagued with problems of administra- 
tion times and drug penetration. Further work is required to 
define the sites of free radical production in reperfused 
myocardium to permit a more specific pharmacologic ap- 
proach. 
Antineutrophil agents. Because neutropenia is known to 
reduce infarct size in the reperfusion model, numerous 
antineutrophil agents (cobra venom factor, prostaglandins, 
nonsteroid antiinflammatory drugs and lipoxygenase inhibi- 
tors) have been studied (94). Most of these agents are 
relatively nonspecific, acting on several neutrophil functions 
by which these cells may mediate reperfusion injury. These 
activities include inhibition of leukocyte-derived chemotac- 
tic factors such as LTB, (nafazatrom), antioxidant effects, 
inhibition of proteolytic enzyme release, increase in intra- 
cellular cyclic AMP (dipyridamole) and interference with 
neutrophil adherence (prostacyclin) (76). These agents were 
recently comprehensively reviewed by Mullane et al. (76); 
however, we must await the study of more specific antineu- 
trophil drugs to unravel the precise mechanisms whereby 
neutrophils mediate reperfusion injury. 
Adenosine. This agent affects the function of various cell 
types thought to be involved in the pathogenesis of reperfu- 
sion injury. Its effects include coronary arteriolar vasodila- 
tion, attenuation of neutrophil-endothelial interactions, inhi- 
bition of platelet aggregation and thromboxane release, 
inhibition of sympathetic neurotransmission and alter- 
ation in intracellular nucleotide and calcium concentrations 
(32,34,36,95). Because the known pharmacologic effects of 
adenosine counteract many of the proposed mechanisms of 
reperfusion injury, we tested this drug in a closed chest 
canine model of reperfusion (13). Selective intracoronary 
administration of adenosine for 1 h after reperfusion in this 
model resulted in a 75% reduction in infarct size compared 
with that in blood-reperfused control animals, and this 
reduction was associated with significant improvement in 
regional ventricular function in the ischemic zone. Whereas 
control animals demonstrated evidence of the no reflow 
phenomenon, regional myocardial blood flow was main- 
tained in the lateral ischemic zones in animals receiving 
adenosine. This increased flow may reflect endothelial- 
independent vascular smooth muscle relaxation or re- 
storation of endothelial-dependent vasodilatory reserve sec- 
ondary to enhanced oxygen delivery to the ischemic 
microvasculature. 
Electron microscopy in the previous study (13) demon- 
strated relative preservation of endothelial cell structure in 
the subendocardium, with reduced neutrophil and red cell 
stagnation of capillaries in the treated group (Fig. 2). In 
addition, light microscopy revealed reduced numbers of 
intravascular and interstitial leukocytes in animals receiving 
adenosine. This finding is in agreement with work by Engler 
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et al. (96) in which pretreatment with S-amino-Cimidazole 
carboxamide-riboside (AICA-riboside), a substance that 
augments adenosine release from energy-deprived cells, 
significantly improved regional myocardial blood flow after 
60 min of ischemia in the dog. 
The observed preservation of endothelial cell structure 
after adenosine administration may be related to replenish- 
ment of high energy phosphate stores, increased oxygen 
delivery or inhibition of neutrophil-mediated endothelial 
damage. As noted earlier (32,37), adenosine inhibits super- 
oxide anion production by the neutrophil and decreases 
neutrophil adherence. The antiplatelet effects of adenosine 
are probably not significant in myocardial reperfusion injury 
because other antiplatelet agents (aspirin and indomethacin) 
do not reduce infarct size (97.98). 
Mechanisms of adenosine action in reperfusion injury. 
The pharmacologic effects of adenosine are mediated by 
adenylate cyclase, involving both receptor and nonreceptor 
mechanisms (99,100). Extracellular surface receptors may 
be stimulatory (A?) or inhibitory (A,) (99). Nonreceptor 
mechanisms include replenishment of nucleotide pools and 
interaction with atypical receptors (the intracellular P site) 
that are present on the cytoplasmic surface of the plasma 
membrane (35). Further studies are needed to clarify the cell 
types and precise mechanism of action of adenosine in 
ameliorating reperfusion injury. These would involve the use 
of specific receptor antagonists (I ,3-dipropyl-8-p sulfo- 
phenylxanthine), adenosine analogue that do not activate the 
receptor (2-chloro-adenosine) and agents that inhibit adeno- 
sine uptake (dipyridamole) (101-103). Such studies may 
allow the development of more specific pharmacologic strat- 
egies to limit reperfusion injury. 
Clinical Implications 
The introduction of new and more potent thrombolytic 
agents and balloon angioplasty has resulted in reperfusion 
therapy as a logical maneuver in the treatment of evolving 
myocardial infarction. However, animal studies have dem- 
onstrated that deleterious events triggered by reperfusion 
may reduce the amount of potentially salvagable myocar- 
dium. The extent of reperfusion injury, therefore, may be an 
important determinant of myocardial damage in patients 
undergoing reperfusion therapy within the first few hours of 
a thrombotic event. Encouraging results in experimental 
studies suggest that limiting no reflow resulting from endo- 
thelial cell disruption and granulocyte plugging may signifi- 
cantly decrease reperfusion injury. 
We thank Edwin K. Jackson. PhD for critical review of the manuscript, and 
Camille Mogan and Carolyn Coffey for secretarial assistance. 
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